Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

NCT05387707 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

287

Enrollment

INDUSTRY

Sponsor class

Stopped In Part A of the study, oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone.

Conditions

Pruritus
Atopic Dermatitis

Interventions

DRUG: difelikefalin 0.25 mg
DRUG: difelikefalin 0.5 mg
DRUG: TCS Cream
DRUG: Placebo
DRUG: Vehicle Cream

Sponsor

Cara Therapeutics, Inc.